Vor Biopharma earnings were $1.4B for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest VOR earnings report on Sep 30, 2026 announced Q3 2026 earnings of -$86.7M, up 38.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VOR reported annual earnings of -$696.0M, with 495.3% growth.
On VOR's earnings call on Oct 30, 2026, Vor Biopharma (NASDAQ: VOR) reported Q3 2026 earnings per share (EPS) of -$1.45, up 98.81% year over year. Total VOR earnings for the quarter were -$86.73 million. In the same quarter last year, Vor Biopharma's earnings per share (EPS) was -$121.63.
As of the last Vor Biopharma earnings report, Vor Biopharma is currently profitable. Vor Biopharma's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $1.35 billion, a 155.26% decrease year over year.
What was VOR's earnings growth in the past year?
As of Vor Biopharma's earnings date in Oct 30, 2026, Vor Biopharma's earnings has grown year over year. VOR earnings in the past year totalled $1.35 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.